MRI contrast developer Epix Medical reported revenues of $2.2 million in its second quarter, down 15.4% compared with the $2.6 million posted in the same period last year. For the quarter (end-June 30), the Cambridge, MA-based firm had a net loss of $5.1 million, compared with a net loss of $4.3 million in the second quarter of 2000.
The lower revenues were attributed to changes in funds received from Schering under a product development deal between the companies, according to Epix. Epix continues to make significant progress, both in advancing its lead product candidate, MS-325, to commercialization, and in selecting a final product candidate as its thrombus imaging agent, said CEO Michael Webb.
By AuntMinnie.com staff writersJuly 27, 2001
Related Reading
Epix trims net loss, April 27, 2001
Epix, InSightec, Brigham and Women's team up, March 12, 2001
Epix loss widens in 2000, February 16, 2001
Schering gains Japanese rights to Epix’s MS-325, January 9, 2001
Copyright © 2001 AuntMinnie.com
